Tag Archives: Biomedical Advanced Research and Development Authority

Regeneron Pharmaceuticals (Nasdaq: REGN) will supply an additional 1.25M treatment courses of an antibody cocktail composed of casirivimab and imdevimab to the U.S. government under a potential $2.63B agreement with the departments of Defense and Health and Human Services.

Pfizer has entered into an agreement with the departments of Health and Human Services and Defense to provide 100M more doses of the messenger RNA-based COVID-19 vaccine that the company developed with pharmaceutical firm BioNTech.

Merck (NYSE: MRK) has reached a $356M deal with the departments of Defense and Health and Human Services to further develop and seek regulatory approval MK-7110, the biopharmaceutical firm's investigational drug for hospitalized COVID-19 patients.

Hologic has secured a $119M contract to increase production capacity for diagnostic kits and test consumables in support of government efforts to sustain the U.S. industrial base through the coronavirus pandemic.

The Department of Health and Human Services has awarded American Type Culture Collection a potential 10-year, $250M contract to provide long-term storage resources for biological specimens and potential vaccines and treatments for the novel coronavirus.

The departments of Health and Human Services and Defense have signed a potential $1.5B agreement with Moderna to produce 100M doses of its COVID-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed.

Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of the biotechnology firm’s vaccine candidate for the novel coronavirus.

The departments of Defense and Health and Human Services awarded contracts worth $2.05B combined to biopharmaceutical companies Novavax and Regeneron to accelerate the manufacture of their respective COVID-19 vaccine and treatment candidates.

The Biomedical Advanced Research and Development Authority has agreed to give materials engineering company Corning approximately $204M to expand manufacturing capacity for glass vials to store potential  vaccines for the novel coronavirus that causes COVID-19.

AstraZeneca and the Department of Health and Human Services have signed a potential $1.2B public-private partnership agreement to further develop a recombinant adenovirus vaccine as potential treatment for the novel coronavirus.